A First in Human Study of RT001 in Patients With Friedreich's Ataxia

Completed · Phase 1/Phase 2

Conditions studied: Friedreich's Ataxia

In brief

The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of RT001 in patients with Friedreich's ataxia.

Key facts

Study ID

NCT02445794

Run by

Biojiva LLC

People needed

19

Starts

2015-08-01

Expected to finish

2016-07-01

Last updated by the study team

2020-11-27

Who can join

Age: 18 and older, up to 50. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female 18 to 50 years of age
• Medical history consistent with the symptoms of FRDA at ≤ 25 years of age
• Homozygous for GAA repeat expansions in the Frataxin gene in the affected range for FRDA
• FARS-Neurological score of 20-90 points
• Ambulatory (with or without assistive device) and capable of performing assessments/evaluations
• Body Mass Index ≤ 29.9 kg/m2
• Agrees to dietary restrictions and agrees to receive calls from a dietary coach
• Signed the informed consent form prior to entry into the study
• Agrees to spend the required number of overnight clinic days
• Able to provide the necessary repeated blood samples

You may not qualify if…

• Received treatment with other experimental therapies within the last 30 days prior to the first dose
• Known point mutation in the FXN gene
• History of malignancies (other than basal cell carcinomas)
• Impaired renal function at screening
• Alanine transaminase (ALT) or aspartate transaminase (AST) laboratory values > 2 x upper limit of normal (ULN) at screening
• Known hepatitis B surface antigen (HBsAg)-positive, or known or suspected active hepatitis C infection, or is known to be human immunodeficiency virus (HIV) positive
• Female who is breastfeeding or has a positive pregnancy test
• Male participant or female participant of child bearing potential, who is sexually active and unwilling/unable to use a medically acceptable and effective double barrier birth control method throughout the study
• Unwilling or unable to comply with the requirements of the protocol
• Clinically significant cardiac abnormalities at screening that, in the opinion of the Investigator, would make the patient unsuitable for enrollment
• Diabetes mellitus (Type 1 or 2)
• Suicidal ideation as determined by the Columbia-Suicide Severity Rating Scale
• History, within the last 2 years, of alcohol abuse, significant mental illness, or physical opioid dependence
• Cannot adhere to the dietary guidance required to be followed by the protocol
• Cannot take the medication due to impairment in swallowing capsules

Where it is running

• Collaborative Neuroscience Network, LLC — Long Beach, California, United States
• University of South Florida — Tampa, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.